摘要
目的:评价格列齐特缓释片联合阿卡波糖治疗2型糖尿病的有效性及安全性。方法:65例2型糖尿病患者根据血糖水平分为3组,分别给予格列齐特缓释片30mg、60mg、120mg,同时联合阿卡波糖片150mg治疗,观察各组血糖、糖化血红蛋白(HbAlc)水平。结果:联合治疗后,全组HbAlc从(8.8±0.75)%下降到(6.83±0.75)%,空腹血糖(FPG)从(9.7±1.86)mmol·L^(-1)下降到(6.56±0.40)mmol·L^(-1),餐后血糖(PPG)从(15.1±2.35)mmol·L^(-1)下降到(8.87±2.1)mmol·L^(-1)。治疗前后比较,差异有统计学意义(P<0.01)。且各剂量级患者治疗后HbAlc、FPG、PPG均较治疗前明显下降(P<0.01)。试验期间发生低血糖事件15次,与药物剂量无关。结论:格列齐特缓释片与阿卡波糖联合治疗可有效的降低2型糖尿病患者的HbAlc、FPG、PPG水平,实现HbAlc达标。
Objective：To evaluate the efficacy and safety of combined treatment with gliclazide and acarbose in type 2 diabetic patients.Methods：65 patients with type 2 diabetes were enrolled in the trial.According to the level of blood glucose,the patients were divided into 3 groups,one is the dose of gliclazide 30mg,another is 60mg,the other is 120mg, combined with acarbose 150 mg,then observe HbAlc、fasting plasma glucose（FPG） and postprandial plasma glucose （PPG）.Results：Compared with the first,HbAI c was reduced from（8.8±0.75 ）%to（6.83±0.75 ）%;FPG from（9.7±1.86）mmol·L^（-1） to（6.56±0.40）mmol·L^（-1）;PPG from（15.1±2.35）mmol·L^（-1）to（8.87±2.1）mmol·L^（-1）.15 cases occured hypoglycema.The hypoglycemia was not correlated with drug dosages.Conclusion：The combined treatment with gliclazide and acarbose in type 2 diabetic patients could effectively reduce HbAlc,FPG,PPG.
出处
《药物流行病学杂志》
CAS
2012年第5期205-206,236,共3页
Chinese Journal of Pharmacoepidemiology
